Multidimensional Analysis of Immune Status of Latent M. Tuberculosis Infection
潜伏结核分枝杆菌感染免疫状态的多维分析
基本信息
- 批准号:9204636
- 负责人:
- 金额:$ 23.7万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-08-03 至 2018-07-31
- 项目状态:已结题
- 来源:
- 关键词:16 year oldAIDS/HIV problemAdolescentAdultAgeAntibodiesAntigensAreaB-LymphocytesBCG VaccineBioinformaticsBiological AssayBiological ProcessBloodCell SeparationCellsCessation of lifeCharacteristicsChildClinicalCohort StudiesCollaborationsComputer AnalysisCytometryData SetDatabasesDetectionDiseaseDisease OutcomeFreezingFrequenciesGene ExpressionGenetic TranscriptionGenus MycobacteriumGoalsHeavy MetalsHumanImmuneImmune responseImmune systemImmunityIncidenceIndividualInfectionInterferon Type IIInterventionInvestigationIsotope LabelingLeadLeukocytesLinkMass Spectrum AnalysisMeasuresMediatingMeta-AnalysisMicroarray AnalysisMolecular ProfilingMycobacterium tuberculosisNatural Killer CellsNeonatalOpportunistic InfectionsPathway interactionsPatientsPatternPeripheral Blood Mononuclear CellPhenotypePopulationPreventive therapyProgressive DiseasePulmonary TuberculosisResearch DesignResearch PersonnelSamplingSignal TransductionSouth AfricaSymptomsSystems AnalysisT-LymphocyteTechniquesTechnologyTherapeuticTimeTuberculosisUniversitiesVaccinesabstractingage groupcell typecohortfollow-upimprovedinsightlatent infectionmortalitynovelresearch studyresponsesuccesstooltranscriptometranscriptome sequencingvaccine candidate
项目摘要
Summary/Abstract
Active tuberculosis (TB) is a major cause of human death and disease. It is also the most common fatal
opportunistic infection in HIV/AIDS worldwide. The current neonatal BCG vaccine does not provide notable
protection against adult pulmonary TB and none of the vaccine candidates show efficacy in board and/or
reliable protection against either infection or disease. Past studies have identified specific immune responses
associated with protection. But simply boosting these responses as employed in most vaccine strategies was
not sufficient to provide protection. Recent experiments indicate that persistent mycobacteria are in an active
state, and that latent infection is maintained though an active immune response. A better understanding of how
latent TB is controlled by the immune system is essential for developing therapeutic hypothesis that could open
new avenues for clinical intervention.
Other than transcriptional analysis, most studies of Mtb responses consist of targeted assays and a focus on
either children or adult populations that show high disease rates. To better understand how latent TB is
controlled, we have created a unique and powerful study design. First, we will use recently developed
technologies, including mass cytometry (CyTOF) and RNAseq for broad, unbiased and high-throughput
analyses. We will apply these powerful new techniques to a material collected from patients between 13-16
years old. This age group stratifies children and adults and is noted to be the “golden age” in TB where
mortality and mobility is low. With this adolescent cohort, we hope to reduce the complexity inherent to latency,
which can vary from something close to sterilizing immunity to subclinical active disease. In addition, we will
employ bioinformatics tools to integrate and infer across two the cellular and transcriptome profiling proposed
in Aim 1 and 2. Furthermore, we will use a novel integrated computationally analyses to compare our results
with other TB studies from public database in Aim 3. Our goal is to gain new insight into how the course of Mtb
infection is controlled in adolescents as compared with that from adults and children, and to identify factors that
mediate and/or predict transitions from latent infection to active disease.
总结/摘要
活动性结核病(TB)是人类死亡和疾病的主要原因。它也是最常见的致命的
机会性感染艾滋病毒/艾滋病的世界各地。目前的新生儿BCG疫苗没有提供显著的
预防成人肺结核,并且没有候选疫苗显示出有效性和/或
对感染或疾病的可靠保护。过去的研究已经确定了特定的免疫反应
与保护有关。但是在大多数疫苗策略中,
不足以提供保护。最近的实验表明,持久性分枝杆菌是在一个活跃的
状态,并通过主动免疫应答维持潜伏感染。更好地了解如何
潜伏性结核病是由免疫系统控制的,这对于开发可能打开
临床干预的新途径。
除了转录分析之外,大多数Mtb应答研究包括靶向测定和重点分析。
无论是儿童还是成年人都显示出高发病率。为了更好地了解结核病的潜伏性
我们创造了一个独特而强大的研究设计。首先,我们将使用最近开发的
技术,包括质谱仪(CyTOF)和RNAseq,用于广泛,无偏倚和高通量
分析。我们将把这些强大的新技术应用于从13-16岁的患者中收集的材料
岁这个年龄组分为儿童和成人,被认为是结核病的“黄金年龄”,
死亡率和流动性低。通过这个青少年群体,我们希望减少延迟固有的复杂性,
其可以从接近于杀菌免疫的东西变化到亚临床活动性疾病。此外,我们将
采用生物信息学工具整合和推断两个细胞和转录组分析提出
目标1和2。此外,我们将使用一种新的综合计算分析来比较我们的结果
与目标3公共数据库中的其他结核病研究进行比较。我们的目标是获得新的见解如何结核病的过程中,
与成人和儿童相比,青少年的感染得到控制,并确定
介导和/或预测从潜伏感染到活动性疾病的转变。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Yueh-Hsiu Chien其他文献
Yueh-Hsiu Chien的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Yueh-Hsiu Chien', 18)}}的其他基金
Multidimensional Analysis of Immune Status of Latent M. Tuberculosis Infection
潜伏结核分枝杆菌感染免疫状态的多维分析
- 批准号:
9325427 - 财政年份:2016
- 资助金额:
$ 23.7万 - 项目类别:
Gamma delta T cells act as rheostats to modulate early B cell response
Gamma delta T 细胞充当变阻器来调节早期 B 细胞反应
- 批准号:
8636277 - 财政年份:2013
- 资助金额:
$ 23.7万 - 项目类别:
Gamma delta T cells act as rheostats to modulate early B cell response
Gamma delta T 细胞充当变阻器来调节早期 B 细胞反应
- 批准号:
8787073 - 财政年份:2013
- 资助金额:
$ 23.7万 - 项目类别:
Regulation and biological impact of IL-17 production by gamma delta T cells
γ δ T 细胞产生 IL-17 的调节和生物学影响
- 批准号:
7897748 - 财政年份:2009
- 资助金额:
$ 23.7万 - 项目类别:
Regulation and biological impact of IL-17 production by gamma delta T cells
γ δ T 细胞产生 IL-17 的调节和生物学影响
- 批准号:
7729096 - 财政年份:2009
- 资助金额:
$ 23.7万 - 项目类别:
Ligands of Gamma Delta T Cell Antigen Receptors
Gamma Delta T 细胞抗原受体的配体
- 批准号:
6850377 - 财政年份:2004
- 资助金额:
$ 23.7万 - 项目类别:
Ligands of Gamma Delta T Cell Antigen Receptors
Gamma Delta T 细胞抗原受体的配体
- 批准号:
6986206 - 财政年份:2004
- 资助金额:
$ 23.7万 - 项目类别:
Ligands of Gamma Delta T Cell Antigen Receptors
Gamma Delta T 细胞抗原受体的配体
- 批准号:
7148708 - 财政年份:2004
- 资助金额:
$ 23.7万 - 项目类别:
Ligands of Gamma Delta T Cell Antigen Receptors
Gamma Delta T 细胞抗原受体的配体
- 批准号:
7532796 - 财政年份:2004
- 资助金额:
$ 23.7万 - 项目类别:
Ligands of Gamma Delta T Cell Antigen Receptors
Gamma Delta T 细胞抗原受体的配体
- 批准号:
7329831 - 财政年份:2004
- 资助金额:
$ 23.7万 - 项目类别:














{{item.name}}会员




